Cargando…
Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature
Introduction: Acinetobacter baumannii (AB) is a multidrug-resistant pathogen commonly associated with nosocomial infections. The resistance profile and ability to produce biofilm make it a complicated organism to treat effectively. Cefoperazone sulbactam (CS) is commonly used to treat AB, but the as...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044834/ https://www.ncbi.nlm.nih.gov/pubmed/36978449 http://dx.doi.org/10.3390/antibiotics12030582 |
_version_ | 1784913444097490944 |
---|---|
author | Kogilathota Jagirdhar, Gowthami Sai Rama, Kaanthi Reddy, Shiva Teja Pattnaik, Harsha Qasba, Rakhtan K. Elmati, Praveen Reddy Kashyap, Rahul Schito, Marco Gupta, Nitin |
author_facet | Kogilathota Jagirdhar, Gowthami Sai Rama, Kaanthi Reddy, Shiva Teja Pattnaik, Harsha Qasba, Rakhtan K. Elmati, Praveen Reddy Kashyap, Rahul Schito, Marco Gupta, Nitin |
author_sort | Kogilathota Jagirdhar, Gowthami Sai |
collection | PubMed |
description | Introduction: Acinetobacter baumannii (AB) is a multidrug-resistant pathogen commonly associated with nosocomial infections. The resistance profile and ability to produce biofilm make it a complicated organism to treat effectively. Cefoperazone sulbactam (CS) is commonly used to treat AB, but the associated data are scarce. Methods: We conducted a systematic review of articles downloaded from Cochrane, Embase, PubMed, Scopus, and Web of Science (through June 2022) to study the efficacy of CS in treating AB infections. Our review evaluated patients treated with CS alone and CS in combination with other antibiotics separately. The following outcomes were studied: clinical cure, microbiological cure, and mortality from any cause. Results: We included 16 studies where CS was used for the treatment of AB infections. This included 11 studies where CS was used alone and 10 studies where CS was used in combination. The outcomes were similar in both groups. We found that the pooled clinical cure, microbiological cure, and mortality with CS alone for AB were 70%, 44%, and 20%, respectively. The pooled clinical cure, microbiological cure, and mortality when CS was used in combination with other antibiotics were 72%, 43%, and 21%, respectively. Conclusions: CS alone or in combination needs to be further explored for the treatment of AB infections. There is a need for randomized controlled trials with comparator drugs to evaluate the drug’s effectiveness. |
format | Online Article Text |
id | pubmed-10044834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100448342023-03-29 Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature Kogilathota Jagirdhar, Gowthami Sai Rama, Kaanthi Reddy, Shiva Teja Pattnaik, Harsha Qasba, Rakhtan K. Elmati, Praveen Reddy Kashyap, Rahul Schito, Marco Gupta, Nitin Antibiotics (Basel) Systematic Review Introduction: Acinetobacter baumannii (AB) is a multidrug-resistant pathogen commonly associated with nosocomial infections. The resistance profile and ability to produce biofilm make it a complicated organism to treat effectively. Cefoperazone sulbactam (CS) is commonly used to treat AB, but the associated data are scarce. Methods: We conducted a systematic review of articles downloaded from Cochrane, Embase, PubMed, Scopus, and Web of Science (through June 2022) to study the efficacy of CS in treating AB infections. Our review evaluated patients treated with CS alone and CS in combination with other antibiotics separately. The following outcomes were studied: clinical cure, microbiological cure, and mortality from any cause. Results: We included 16 studies where CS was used for the treatment of AB infections. This included 11 studies where CS was used alone and 10 studies where CS was used in combination. The outcomes were similar in both groups. We found that the pooled clinical cure, microbiological cure, and mortality with CS alone for AB were 70%, 44%, and 20%, respectively. The pooled clinical cure, microbiological cure, and mortality when CS was used in combination with other antibiotics were 72%, 43%, and 21%, respectively. Conclusions: CS alone or in combination needs to be further explored for the treatment of AB infections. There is a need for randomized controlled trials with comparator drugs to evaluate the drug’s effectiveness. MDPI 2023-03-15 /pmc/articles/PMC10044834/ /pubmed/36978449 http://dx.doi.org/10.3390/antibiotics12030582 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Kogilathota Jagirdhar, Gowthami Sai Rama, Kaanthi Reddy, Shiva Teja Pattnaik, Harsha Qasba, Rakhtan K. Elmati, Praveen Reddy Kashyap, Rahul Schito, Marco Gupta, Nitin Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature |
title | Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature |
title_full | Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature |
title_fullStr | Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature |
title_full_unstemmed | Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature |
title_short | Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature |
title_sort | efficacy of cefoperazone sulbactam in patients with acinetobacter infections: a systematic review of the literature |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044834/ https://www.ncbi.nlm.nih.gov/pubmed/36978449 http://dx.doi.org/10.3390/antibiotics12030582 |
work_keys_str_mv | AT kogilathotajagirdhargowthamisai efficacyofcefoperazonesulbactaminpatientswithacinetobacterinfectionsasystematicreviewoftheliterature AT ramakaanthi efficacyofcefoperazonesulbactaminpatientswithacinetobacterinfectionsasystematicreviewoftheliterature AT reddyshivateja efficacyofcefoperazonesulbactaminpatientswithacinetobacterinfectionsasystematicreviewoftheliterature AT pattnaikharsha efficacyofcefoperazonesulbactaminpatientswithacinetobacterinfectionsasystematicreviewoftheliterature AT qasbarakhtank efficacyofcefoperazonesulbactaminpatientswithacinetobacterinfectionsasystematicreviewoftheliterature AT elmatipraveenreddy efficacyofcefoperazonesulbactaminpatientswithacinetobacterinfectionsasystematicreviewoftheliterature AT kashyaprahul efficacyofcefoperazonesulbactaminpatientswithacinetobacterinfectionsasystematicreviewoftheliterature AT schitomarco efficacyofcefoperazonesulbactaminpatientswithacinetobacterinfectionsasystematicreviewoftheliterature AT guptanitin efficacyofcefoperazonesulbactaminpatientswithacinetobacterinfectionsasystematicreviewoftheliterature |